Vivet Therapeutics

A single-dose AAV gene therapy designed to restore the bile transporter missing in progressive familial intrahepatic cholestasis type 2; and what a new preclinical study showed. THE DISEASE Why PFIC2 is hard to treat PFIC2 is a rare, inherited liver disea

VTX-PID as a novel recombinant immunoglobulin G-degrading enzyme (IdeS) for efficient AAV-based gene therapy in participants with neutralizing antibodies: results of the phase I first-in-human NAVIgATE study Breaking barriers in AAV gene therapy : The NAb

Paris, 6th May 2026 - At the Annual Congress of the American Society of Gene & Cell Therapy (ASGCT), Vivet Therapeutics will present translational modeling data supporting the ability of its proprietary VTX-PID imlifidase formulation to enable AAV gene th

Paris, 6th May 2026 - At the Annual Congress of the American Society of Gene & Cell Therapy (ASGCT), Vivet Therapeutics will present translational modeling data supporting the ability of its proprietary VTX-PID imlifidase formulation to enable AAV gene th

Vivet Therapeutics is pleased to announce that our CEO, Jean-Philippe Combal, will be attending the Jefferies Global Healthcare Conference in London from November 18th to 20th, 2025. As we join this leading global event, we are excited to present our late

Sevilla, October 2025 - At the 32nd Annual Congress of the European Society of Gene & Cell Therapy (ESGCT), Vivet Therapeutics shared new clinical data with its VTX-PID proprietary imlifidase formulation, highlighting the effective reduction of neutralizi

Join our CEO, @Jean-Philippe Combal in the Big Apple for @Chardan's 9th Annual Genetic Medicines Conference! The premier event will bring together groundbreaking thought leaders to discuss major themes in genetic medicines through fireside chats, individu

Join us at ESGCT 2025 in Sevilla for an important presentation by Jean-Philippe Combal from Vivet Therapeutics on October 9th at 10:00am CET during the session entitled Immune responses to gene therapy. https://lnkd.in/enSxNwzFLearn how VTX-PID (imlifidas

Vivet Therapeutics is excited to announce two poster presentations at ESGCT 2025 in Sevilla, showcasing innovative advances in liver-directed gene therapy. Catch us on Thursday, October 9th, from 14:00 to 15:30 CEST: Poster P0966: "Evaluation of Liver-Dir

We are excited to share our paper on Pilot clinical study showing abnormal copper metabolism in healthy Wilson disease heterozygote subjects, accepted to CTSJournal. See it here : https://lnkd.in/e-rzZnXp #ASCPTJournalFamily - Wilson Disease Association 6